The zebrafish erbb2 mutant thus could serve as an in vivo platform for phenotype-based drug screen to identify novel small molecules capable of suppressing CHD-associated hypertrophic cardiomyopathy. This evidence concerns the gene ERBB2 and coronary artery disorder.